度洛西汀与氟西汀治疗躯体形式障碍对照研究

A control study of duloxetine versus fluoxetine in the treatment of somatoform disorders

目的：探讨度洛西汀与氟西汀治疗躯体形式障碍的临床疗效和安全性。方法将80例躯体形式障碍患者随机分为两组，研究组口服度洛西汀治疗，对照组口服氟西汀治疗，观察6周。于治疗前后采用临床疗效大体评定量表、症状自评量表的躯体化、焦虑、抑郁因子评定临床疗效，副反应量表评定不良反应。结果治疗6周末，研究组显效率69．2％、总有效率89．7％，对照组分别为44．4％、75．0％，研究组显效率显著高于对照组（χ2＝4．70，P＜0．05），总有效率高于对照组，但差异无显著性（χ2＝2．84，P＞0．05）。治疗各时段副反应量表评分均显著低于对照组（P＜0．01）。结论度洛西汀与氟西汀治疗躯体形式障碍疗效均显著，但度洛西汀治疗起效更快、疗效更显著、安全性更高、依从性更好。

Objective To explore the efficacy and safety of duloxetine and fluoxetine in the treatment of somatoform disorders .Methods Eighty patients with somatoform disorders were randomly divided into two groups ,research took orally duloxetine and control group did fluoxetine for 6 weeks .Efficacies were assessed with the Clinical Global Impression （CGI） and somzatization ,anxiety and depression factor of the Symptom Checklist-90 （SCL-90） before and after treatment and adverse effects with the Treatment Emer-gent Symptom Scale （TEES） .Results At the end of the 6th week obvious effective rate was significantly higher in research than control group （69 .2% vs .44 .4% ,χ2 =4 .70 ,P〈0 .05） ,total effective rate higher but not significant （89 .7% vs .75 .0% ,χ2 =2 .84 ,P〉0 .05） .The scores of the TESS at each period were significantly lower in research than in control group （P〈0 .01） .Conclusion Both dluoxetine and fluoxe-tine have an evident effect in the treatment of somatoform disorders ,but the former takes effect more rap-idly and has a more evident effect ,higher safety and better compliance .